Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)

Abstract

Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease‐19 (COVID‐19). Although placebo‐controlled, double‐blind randomised clinical trials are lacking, current data from either retrospective, case series or open‐label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID‐19 patients. See alsoShao et al.

Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq

“…With the support of our esteemed professor, we presented a multi-country survey of COVID-19 to characterize mortality-associated factors in elderly males with comorbidities [111] . In addition to remdesivir and dexamethasone, many strategies are still under development to treat COVID-19 [113] , [114] , [115] , [116] , [117] , [118] , [119] , [120] , [121] , [122] , [123] , [124] , [125] , [126] , [127] .…”

Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article

“…IVIg therapy contains immunoglobulin G obtained from pooled type healthy donor plasma that can act on both body initiative and adaptive immune type. [38,39] Additionally, IVIg was previously indicated in managing neuroimmunological diseases such as MS and myasthenia gravis. [38,39] Although the use of IVIg on COVID-19 patients is somehow limited, the risk of increasing disease-related severity including neurological symptoms is considered mild.…”

“…[38,39] Additionally, IVIg was previously indicated in managing neuroimmunological diseases such as MS and myasthenia gravis. [38,39] Although the use of IVIg on COVID-19 patients is somehow limited, the risk of increasing disease-related severity including neurological symptoms is considered mild. It was reported that IVIg is effective against thromboembolism and elevated D-dimer levels in hospitalized COVID-19 patients.…”

How IvIg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model

“…One of these approaches is injection of intravenous immunoglobulin (IvIg) to mitigate the disease, (6) supported by recent reports. (7)(8)(9)(10) It is commonly accepted that the severity of disease is caused by an overacting immune response producing a cytokine storm. (11) To optimize the immune-modulatory effect a better understanding of how IvIg changes the immune response to the infection would be helpful.…”